hepatotoxicity


Also found in: Thesaurus, Medical, Encyclopedia, Wikipedia.

hep·a·to·tox·ic·i·ty

 (hĕp′ə-tō-tŏk-sĭs′ĭ-tē, hĭ-păt′ō-)
n.
1. The quality or condition of being toxic or destructive to the liver.
2. The capacity of a substance to have damaging effects on the liver.

hep′a·to·tox′ic (-tŏk′sĭk) adj.

hepatotoxicity

(ˌhɛpətəʊtɒkˈsɪsɪtɪ)
n
(Medicine) the state or quality of being hepatoxic
Translations

hep·a·to·tox·ic·i·ty

n. hepatotoxicidad, la tendencia de un fármaco o producto tóxico a dañar el hígado.
References in periodicals archive ?
Further, the report states that adverse effects such as hepatotoxicity, hyperglycemia, hyperlipidemia, lactic acidosis, lipodystrophy, osteonecrosis, osteopenia, osteoporosis, and skin rash presents a significant challenge to this market.
However, the hepatotoxicity of triptolide always limits its clinical applications.
Other case reports were about Black Cohosh-induced hepatotoxicity leading to early cirrhosis, acute liver failure following consumption of a popular sugar-free energy drink for a year and a case of drug-induced liver injury arising from ripped fuel.
First-line anti-TB drugs associated with hepatotoxicity are isoniazid (INH), rifampicin (RIF) and pyrazinamide (PZA).
Because of the reported hepatotoxicity associated with this drug, liver function testing is routinely performed on patients while they are on eltrombopag therapy.
Regular monitoring is required for both treatments, particularly methotrexate to prevent significant bone marrow suppression and hepatotoxicity.
This preparation was developed to minimize flushing and hepatotoxicity seen with immediate-release (Niacor), and "sustained-release" forms, the latter being of different composition and not FDA approved, but currently sold as dietary supplements.
We report on two women with hyperbilirubinaemia caused by druginduced hepatotoxicity in early pregnancy.
There are concerns about overlapping drug toxicity, and of hepatotoxicity in particular, but the advice is to use an efavirenz-based rather than nevirapine-based ART regimen.
Scott Siler, DILI-sim Consultant, will present a webinar “The DILIsym model and its application to hepatotoxicity testing in drug development” on Tuesday, June 19, 2012 at 1:00 - 2:00 pm EDT as part of Rosa's ongoing monthly public webinar series.
Committee members did express reservations about the paucity of data with regard to neoplasms, hepatotoxicity events, and hypersensitivity reactions.
The committee members were particularly concerned about an increased incidence of neoplasm serious adverse events new malignant events in the group on 100 mg mirabegron in the 1-year study, as well as hepatotoxicity events and hypersensitivity reactions.